Diahann T S L Jansen
Overview
Explore the profile of Diahann T S L Jansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
den Hollander N, Jansen D, Roep B
J Clin Med
. 2025 Jan;
14(2).
PMID: 39860427
Thymoglobulin is used to prevent allograft rejection and is being explored at low doses as intervention immunotherapy in type 1 diabetes. Thymoglobulin consists of a diverse pool of rabbit antibodies...
2.
Kessler A, Pieterman R, Doff W, Bezstarosti K, Bouzid R, Klarenaar K, et al.
NPJ Vaccines
. 2025 Jan;
10(1):12.
PMID: 39827205
Synthetic long peptides (SLPs) are a promising vaccine modality that exploit dendritic cells (DC) to treat chronic infections or cancer. Currently, the design of SLPs relies on in silico prediction...
3.
Jansen D, Nikolic T, den Hollander N, Zwaginga J, Roep B
Genes (Basel)
. 2024 Nov;
15(11).
PMID: 39596627
Background/objectives: Dendritic cells (DCs) are master regulators of the adaptive immune response. Inflammatory DCs (inflamDCs) can prime inflammatory T cells in, for instance, cancer and infection. In contrast, tolerogenic DCs...
4.
van Tienhoven R, Jansen D, Park M, Williams J, Larkin J, Quezada S, et al.
Front Immunol
. 2024 Apr;
15:1384406.
PMID: 38596681
Introduction: The autoimmune response in type 1 diabetes (T1D), in which the beta cells expressing aberrant or modified proteins are killed, resembles an effective antitumor response. Defective ribosomal protein products...
5.
Jansen D, de Beijer M, Luijten R, Kwappenberg K, Wiekmeijer A, Kessler A, et al.
Front Immunol
. 2023 Oct;
14:1163118.
PMID: 37781393
Introduction: Therapeutic vaccination based on synthetic long peptides (SLP) containing both CD4+ and CD8+ T cell epitopes is a promising treatment strategy for chronic hepatitis B infection (cHBV). Methods: We...
6.
Buschow S, Jansen D
Cells
. 2021 Jun;
10(5).
PMID: 34066322
The impaired T cell responses observed in chronic hepatitis B (HBV) patients are considered to contribute to the chronicity of the infection. Research on this impairment has been focused on...
7.
Dou Y, Jansen D, van den Bosch A, de Man R, van Montfoort N, Araman C, et al.
Antiviral Res
. 2020 Feb;
178:104746.
PMID: 32081741
Synthetic long peptide (SLP) vaccination is a promising new treatment strategy for patients with a chronic hepatitis B virus (HBV) infection. We have previously shown that a prototype HBV-core protein...
8.
de Beijer M, Jansen D, Dou Y, van Esch W, Mok J, Maas M, et al.
J Virol
. 2019 Dec;
94(7).
PMID: 31852786
Immunotherapy represents an attractive option for the treatment of chronic hepatitis B virus (HBV) infection. The HBV proteins polymerase (Pol) and HBx are of special interest for antigen-specific immunotherapy because...
9.
Koppejan H, Jansen D, Hameetman M, Thomas R, Toes R, van Gaalen F
Arthritis Res Ther
. 2019 Jan;
21(1):3.
PMID: 30611306
Background: Mucosal-associated invariant T (MAIT) cells are innate-like T cells that recognise bacterial metabolites presented by MHC class I-related protein 1 (MR1). Bacterial dysbiosis has been implicated in auto-inflammatory disease...
10.
Jansen D, Emery P, Smolen J, Westhovens R, Le Bars M, Connolly S, et al.
RMD Open
. 2018 Apr;
4(1):e000564.
PMID: 29657830
Objective: To evaluate the effects of the T-cell costimulation blocker abatacept on anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) in early rheumatoid arthritis (RA), and associations between changes in...